Definium Therapeutics Us, Inc.
Clinical trials sponsored by Definium Therapeutics Us, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a modified MDMA ease autism symptoms? small trial begins Results expected Aug 2027 (estimated)
- Could a Psychedelic-Like pill beat depression? phase 3 trial underway Results expected Sep 2027 (estimated)
-
Could a tiny dose of LSD help adults with ADHD?
Disease control CompletedThis study tested whether repeated low doses of LSD (called MM120) can safely help adults with ADHD. Fifty-three adults took either the drug or a placebo, and researchers measured changes in ADHD symptoms using a standard rating scale. The goal was to see if this approach could b…
Phase 2 • Sponsor: Definium Therapeutics US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
LSD shows promise for anxiety in new clinical trial
Symptom relief CompletedThis Phase 2 study tested four different doses of MM120 (a form of LSD) against a placebo in 198 people with generalized anxiety disorder. The goal was to see which dose best reduces anxiety symptoms over 4 to 8 weeks. Participants took a single dose and were monitored for safety…
Phase 2 • Sponsor: Definium Therapeutics US, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC